Pooled Procurement Mechanism (PPM)

Procurement Service Agents and Partner Organizations' Allocations, and Fees

26th March 2026

Health Product Category	Effective From	Reference Fees*	Organization
Antiretroviral Medicines (ARV)	3 September 2025	0.90%**	i+ solutions
Antimalarial Medicines (ANTM)			
Essential Medicines for HIV, Malaria & Tuberculosis Programs			
Insecticide Resistant Nets (ITN)	30 June 2025	1.95%	IDA
Commodities & Insecticides for Indoor Residual Spraying (IRS)		3.75%	
Rapid Diagnostic Tests for HIV & Malaria Program (RDT)		2.96%	PFSCM
Viral Load & Early Infant Diagnostics (VL/EID) ***			
Other Diagnostics for HIV, Tuberculosis & Malaria Programs ****			
Laboratory & Medical Supplies; Medical Equipment & Devices			
Condoms & Lubricants *****	1 January 2026	3.5%	PFSCM

** Reference Fees are effective upon ePO issued date*
*** PSA Reference Fees for Lenacapavir products only is 1.20%*
**** This includes products, where the PSA invoices and price quotations the Reference Fee as a percentage of what the equipment, re-agents & associated ordered products (e.g. rental agreements' procurement) would have cost if the PR had bought the product.*
***** PSA Reference Fee for TB Near Point of Care Products from Pluslife is 4.0%*
****** For UNFPA condom and lubricant orders placed between 1 July 2024 to 31 December 2025, the PSA Reference Fee was 7.0% based on the CIF value (not product value alone).*

Notes:

- The PSA Reference Fee is expressed as a percentage of the total price of the products (excluding customs duty and other taxes, transport and insurance) based on the vendor's unit price stated on the purchase order.
- For those requisitions in process during the implementation of the new fee structure there may be downward adjustments to the fees charged should it be material.
- The Reference Fee can change without prior notice, please check with the Global Fund PPM team for the latest information.
- For other health products, not listed here, contact the Global Fund.

Archive PSA Reference Fees

Health Product Category	Effective From	Reference Fees[#]	Organization
COVID-19 Response Diagnostic Products	As currently	3.0%	PFSCM
Therapeutics for COVID-19 Response Products		2.5%	i+ solutions
Personal Protective Equipment for COVID-19 Response Products			
Commodities for COVID-19 Response Oxygen Products [##]			

[#] Reference Fees are effective upon ePO issued date
[##] Commodities for Oxygen Supply for COVID-19 Response refers to products and equipment (and services, where applicable) designed and manufactured to ensure the use of oxygen as a medical treatment, and are stated in the Global Fund Health Product Management Template (HPMT) categories: Medical Oxygen - Consumables, Medical Oxygen - Liquid Oxygen and Medical Oxygen - Equipment. Examples of COVID-19 related Oxygen Products are nasal prongs, oxygen plants, non-invasive ventilators and oxygen concentrator.